Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
← catalyst calendarNCT05611931 · readout ≤ 12 d
Sponsored by Karyopharm Therapeutics Inc (industry) · KPTI — their whole pipeline →. With GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology and 8 more.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-18 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Endometrial Cancer
Interventions
- Drug: Selinexor — also filed as KPT-330
- Drug: Matching Placebo for selinexor
Primary outcome
what the primary-completion date above is the date OFPublications
- PMID 40966692 — linked by the registry
- PMID 38834399 — linked by the registry
- PMID 38627035 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · KPTI's whole pipeline · Catalyst calendar · Every registered study · What changed